QuidelOrtho provides three-year outlook at investor day

Sees FY25 EPS $6.00-$7.00. Sees FY25 adjusted EBITDA margin 27%-29%. Sees three-year target adjusted free cash flow conversion 27%-29%. Sees three-year adjusted EBITDA margin expansion of 25-50 basis points. Comments taken from investor day presentation slides.